Literature DB >> 32014533

Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.

Javier Jimenez1, Eran C Gwillim1, Cory Kosche1, Anna Figueiredo1, Corrine Rauck1, Stephanie M Rangel1, Jennifer Choi1, Dennis P West1, Beatrice Nardone2, Mario E Lacouture3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32014533      PMCID： PMC8207244          DOI： 10.1016/j.jaad.2020.01.059

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  3 in total

1.  Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.

Authors:  Jacob Siegel; Mariam Totonchy; William Damsky; Juliana Berk-Krauss; Frank Castiglione; Mario Sznol; Daniel P Petrylak; Neal Fischbach; Sarah B Goldberg; Roy H Decker; Angeliki M Stamatouli; Navid Hafez; Earl J Glusac; Mary M Tomayko; Jonathan S Leventhal
Journal:  J Am Acad Dermatol       Date:  2018-07-17       Impact factor: 11.527

Review 2.  Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.

Authors:  June M McKoy; Matthew J Fisher; D Mark Courtney; Dennis W Raisch; Beatrice J Edwards; Marc H Scheetz; Steven M Belknap; Steven M Trifilio; Athena T Samaras; Dustin B Liebling; Beatrice Nardone; Katrina Marie Tulas; Dennis P West
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

Review 3.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738
  3 in total
  1 in total

Review 1.  Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.

Authors:  Rohan R Shah; Chinmoy Bhate; Amanda Hernandez; Chin Hung Ho
Journal:  Dermatol Ther       Date:  2022-03-15       Impact factor: 3.858
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.